Acute Ischemic Stroke Clinical Trial
— PROTECTOfficial title:
Effect of Ischemic Post-conditioning on Infarct Volume in Patients With Acute Ischemic Stroke After Mechanical Thrombectomy
Ischemic post-conditioning is a neuroprotective strategy attenuating reperfusion injury in animal stroke models. The investigators have conducted a 3 + 3 dose-escalation trial to demonstrate the safety and tolerability of ischemic post-conditioning incrementally for a longer duration of up to 5 min × 4 cycles in stroke patients undergoing mechanical thrombectomy. This study aims to assess the infarct volume after ischemic post-conditioning in patients with acute ischemic stroke who are treated with mechanical thrombectomy.
Status | Recruiting |
Enrollment | 20 |
Est. completion date | March 31, 2024 |
Est. primary completion date | December 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age = 18 years; - Acute ischemic stroke within 24 hours from stroke onset (or from time last known well) to groin puncture; - Previous mRS = 2; - Baseline NIHSS = 6; - Baseline ASPECTS = 6; - With an occlusion of unilateral middle cerebral artery M1 segment/distal intracranial carotid artery; - Successful recanalization (mTICI = 2b) after thrombectomy confirmed by DSA; - Written informed consent provided by the patients or their legal relatives. Exclusion Criteria: - Confirmed or clinically suspected cerebral vasculitis/fibromuscular dysplasia; - Difficulty in reaching the designated position of the balloon used for ischemic post-conditioning; - Stenting in the middle cerebral artery M1 segment/distal intracranial carotid artery during thrombectomy; - > 2 times balloon dilations as rescue therapy due to angioplasty during thrombectomy; - Moderate/severe residual stenosis (= 50%) in the offending artery after thrombectomy; - Patients with contraindications to MRI; - Other conditions that the investigator considered inappropriate for inclusion. |
Country | Name | City | State |
---|---|---|---|
China | Tianjin Huanhu Hospital | Tianjin |
Lead Sponsor | Collaborator |
---|---|
Capital Medical University |
China,
Wu L, Zhang B, Zhao W, Ji X, Wei M. Ischemic post-conditioning in acute ischemic stroke thrombectomy: A phase-I duration escalation study. Front Neurosci. 2022 Dec 8;16:1054823. doi: 10.3389/fnins.2022.1054823. eCollection 2022. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Safety outcome (mortality at 90 days) | 90-day mortality | 90 days after procedure | |
Other | Safety outcome (the proportion of symptomatic intracranial hemorrhage within 24 hours) | The proportion of symptomatic intracranial hemorrhage within 24 hours after procedure | Within 24 hours after procedure | |
Other | Safety outcome (the proportion of intracranial hemorrhage within 24 hours) | The proportion of intracranial hemorrhage within 24 hours after procedure | Within 24 hours after procedure | |
Other | Safety outcome (the proportion of malignant brain edema within 24 hours) | The proportion of malignant brain edema within 24 hours after procedure | Within 24 hours after procedure | |
Other | Procedure-related complications | Vascular perforation/rupture, vessel dissection, severe vasospasm, rupture of the balloon used for post-conditioning | During the procedure | |
Primary | Infarct volume | Infarct volume at 72 hours after procedure | 72 hours after procedure | |
Secondary | The progression of infarct volume | Difference of infarct volume between baseline and 72 hours after procedure | Baseline and 72 hours after procedure | |
Secondary | The proportion of functional independence at 90 days | The modified Rankin Scale (mRS) score of 0-2 at 90 days after procedure; the mRS is an ordinal disability score of 7 categories (0=no symptoms to 5=severe disability, and 6=death) | 90 days after procedure | |
Secondary | The proportion of favorable outcome at 90 days | The mRS score of 0-3 at 90 days after procedure; the mRS is an ordinal disability score of 7 categories (0=no symptoms to 5=severe disability, and 6=death) | 90 days after procedure | |
Secondary | The distribution of the mRS score at 90 days | The distribution of the mRS score at 90 days after procedure; the mRS is an ordinal disability score of 7 categories (0=no symptoms to 5=severe disability, and 6=death) | 90 days after procedure | |
Secondary | National Institute of Health Stroke Scale (NIHSS) score | NIHSS score at 24 hours after procedure; the NIHSS ranges from 0 to 42, with higher scores indicating more severe neurologic deficits | 24 hours after procedure | |
Secondary | The proportion of early neurological improvement | NIHSS 0-2 or =8 lower than baseline NIHSS score at 24 hours after procedure; the NIHSS ranges from 0 to 42, with higher scores indicating more severe neurologic deficits | 24 hours after procedure | |
Secondary | NIHSS score at 7 days after procedure/discharge | NIHSS score at 7 days after procedure/discharge; the NIHSS ranges from 0 to 42, with higher scores indicating more severe neurologic deficits | 7 days after procedure/discharge | |
Secondary | Recanalization rate | Recanalization rate at 24 hours after procedure (mTICI =2b) | 24 hours after procedure | |
Secondary | Hemodynamic assessment | Hemodynamic assessment within 24 hours after procedure | Within 24 hours after procedure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06113848 -
Adjunctive Use of Intra-Arterial TNK and Albumin Following Thrombectomy
|
Phase 3 | |
Completed |
NCT04069546 -
The Efficacy of Remote Ischemic Conditioning on Stroke-induced Immunodeficiency
|
N/A | |
Active, not recruiting |
NCT05700097 -
Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy
|
Phase 2 | |
Recruiting |
NCT06058130 -
Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis
|
N/A | |
Recruiting |
NCT04415164 -
Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke
|
Phase 4 | |
Recruiting |
NCT05363397 -
Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke
|
Phase 2 | |
Completed |
NCT05429658 -
Single Arm Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System
|
N/A | |
Recruiting |
NCT05390580 -
Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct
|
N/A | |
Enrolling by invitation |
NCT05515393 -
A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke
|
Phase 2 | |
Active, not recruiting |
NCT05070260 -
ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo
|
Phase 2/Phase 3 | |
Terminated |
NCT05547412 -
Validation of Velocity Curvature Index as a Diagnostic Biomarker Tool for Assessment of Large Vessel Stroke
|
||
Completed |
NCT03366818 -
New Stent Retriever, VERSI System for AIS
|
N/A | |
Not yet recruiting |
NCT05293080 -
Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE
|
Phase 3 | |
Not yet recruiting |
NCT06040476 -
Human Umbilical Cord Blood Infusion in Patients With Acute Ischemic Stroke (AIS)
|
Phase 2 | |
Not yet recruiting |
NCT06437431 -
Glenzocimab in Anterior Stroke With Large Ischemic Core Eligible for Endovascular Therapy
|
Phase 2/Phase 3 | |
Completed |
NCT02223273 -
Brazilian Intervention to Increase Evidence Usage in Practice - Stroke (BRIDGE-Stroke)
|
N/A | |
Completed |
NCT02586233 -
Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke
|
Phase 1/Phase 2 | |
Terminated |
NCT01694381 -
Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor
|
Early Phase 1 | |
Not yet recruiting |
NCT01594190 -
Physical Activity Immediately After Acute Cerebral Ischemia
|
N/A | |
Completed |
NCT01120301 -
Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3)
|
Phase 3 |